These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3457103)

  • 1. High dose Ara-C related leukoencephalopathy.
    Hwang TL; Yung WK; Lee YY; Borit A; Fields WS
    J Neurooncol; 1986; 3(4):335-9. PubMed ID: 3457103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible treatment-related leukoencephalopathy.
    Gay CT; Bodensteiner JB; Nitschke R; Sexauer C; Wilson D
    J Child Neurol; 1989 Jul; 4(3):208-13. PubMed ID: 2768785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
    Early AP; Preisler HD; Slocum H; Rustum YM
    Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical effect and pharmacokinetics of intermediate dose Ara-C therapy in a patient with acute non-lymphocytic leukemia with two CNS recurrences].
    Fukushima T; Ueda T; Kamiya K; Yoshida W; Tsutani H; Uchida M; Nakamura T; Kagawa D; Domae N
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):126-31. PubMed ID: 2324584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukoencephalopathy following high-dose intravenous methotrexate chemotherapy: quantitative assessment of white matter attenuation using computed tomography.
    Allen JC; Thaler HT; Deck MD; Rottenberg DA
    Neuroradiology; 1978; 16():44-7. PubMed ID: 740209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progressive ascending paralysis following administration of intrathecal and intravenous cytosine arabinoside. A Pediatric Oncology Group study.
    Dunton SF; Nitschke R; Spruce WE; Bodensteiner J; Krous HF
    Cancer; 1986 Mar; 57(6):1083-8. PubMed ID: 3455842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged high dose ARA-C infusions in acute leukemia.
    Spriggs DR; Robbins G; Arthur K; Mayer RJ; Kufe D
    Leukemia; 1988 May; 2(5):304-6. PubMed ID: 3287017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia.
    Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR
    J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H; Yamauchi T; Gotoh N; Sugiyama M; Ueda T
    Anticancer Res; 2003; 23(6D):5037-42. PubMed ID: 14981964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
    Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
    Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement.
    Castagnola C; Nozza A; Corso A; Bernasconi C
    Haematologica; 1997; 82(5):577-80. PubMed ID: 9407724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia.
    Heinemann V; Estey E; Keating MJ; Plunkett W
    J Clin Oncol; 1989 May; 7(5):622-8. PubMed ID: 2709090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
    Kumagawa M; Suzuki K; Nagano M; Takamatsu Y; Suzumiya J; Tamura K
    Rinsho Ketsueki; 2003 Jun; 44(6):404-6. PubMed ID: 12884821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
    Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
    Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
    Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
    J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
    Lin SF; Liu HW; Chen TP
    Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia].
    Thomas X; Archimbaud E
    Bull Cancer; 1995 Nov; 82(11):911-22. PubMed ID: 8535017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
    Willemze R; Jager U; Jehn U; Stryckmans P; Bury J; Suciu S; Solbu G; Zittoun R; Burghouts J; Löwenberg B
    Eur J Cancer Clin Oncol; 1988 Nov; 24(11):1721-5. PubMed ID: 3061827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical MRI findings in treatment-related leukoencephalopathy: case report.
    Ohmoto Y; Kajiwara K; Kato S; Nisizaki T; Ito H; Tamura S
    Neuroradiology; 1996 Feb; 38(2):128-33. PubMed ID: 8692421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.